Are you interested in investing in Vaxart biotech company shares and therefore wish to learn more about this company? In this case we invite you to read this dedicated article with its useful information on the share price and its quotation as well as the issuing company, its principal activities and sources of revenue, its direct competitors on the market and also its recent partnerships. We will also explain how to implement a comprehensive fundamental analysis of this asset with details of the factors you should monitor in priority.
As the Vaxart Company is specialised in the biotechnology sector, it is clearly necessary to closely follow the projects it is working on as well as advances achieved in terms of research and clinical trials currently underway. We would therefore recommend you monitor the different trial phases and results obtained as well as the market launch rights obtained for fully developed products.
It is also important to monitor the strategic partnerships that the group could implement, notably with large pharmaceutical companies with the aim of financing research and obtaining higher visibility on the market.
The implementation of new projects instigating from current research into new medical infections is also a factor to take into consideration.
We would also of course monitor this group’s competitors particularly developments achieved by other biotech companies specialised in the same areas that could discover vaccine candidates before Vaxart.
Finally it is also important to stay informed on all the communications and announcements of this group relating to its growth strategy as well as the publication of its quarterly and annual results. You can find all this information on this group’s official website in the section reserved for investors and shareholders.
We will now embark on a detailed presentation of the Vaxart Company and its principal activities. In fact, knowing this company and its specialisations and particularities is necessary to be able to understand the challenges it faces and its possibilities for future growth.
Vaxart Inc. is an American biotechnology company that was previously known as Aviragen Therapeutics. More precisely, this company is specialised in the discovery and development of direct action anti-virals for treating infections that affect patients worldwide.
Currently, the Vaxart Company is developing three candidate products for the clinical development and treatment of viral infections for which the therapeutic options are limited.
Among its products we particularly note Vapendavir which is an oral treatment for the upper respiratory tract human rhinovirus infections or HRV in moderate and severe asthmatic patients in the phase IIb SPIRITUS study, BTA 585 which is an oral fusion protein inhibitor in phase II development for the treatment and prevention of RSV or respiratory syncytial virus infections. Finally, there is also BTA074 which is a topical phase II anti-viral treatment for condyloma caused by the human papillomavirus types 6 and 11.
The group also has a preclinical programme of RSV non-fusion inhibitors and has concentrated its medical research and development abilities on the discovery and development of small molecules able to prevent and treat infectious diseases.
The Vaxart Company currently employs 28 people.
We offer you now the opportunity to learn more in detail about the principal adversaries of the Vaxart Company in its activity sector with a presentation of its three major competitors:
Firstly, the Compugen Company is a discovery and development company for predictive medications at a clinical trial stage. This company is quoted on the stock markets and based in Israel. Its shares are traded on the Nasdaq Capital Market and the Tel Aviv stock market. In the beginning this company was created as a supplier of IT services related to medical development for the pharmaceutical companies. The group then became a medical development company with its own internal pipeline and notably concentrated its efforts in oncology and immunology.
Another competitor of Vaxart is the biopharmaceuticals company Molecular Templates which is specialised in the discovery and development of next generation ETB immunotoxins which constitute a new class of therapeutic products with a unique biology and a differentiated active mechanism. These ETBs are conceived and created with the aim of inducing their own internalisation against non internalised receptors to destruct tumour cells that are resistant to other modalities.
Finally, the Kadmon Company is a biopharmaceutical company specialised in the discovery and development as well as the sale of small molecules and biological products for treatments relating to illnesses and medical care that are unsatisfied. It notably develops product candidates for auto-immune and fibrotic illnesses as well as oncology and genetic diseases. The group boasts a multidisciplinary team for clinical research and development that have already launched over a dozen new medical products and continue to develop new medicines through licensed products using small molecules and biological platforms.
Following our examination of Vaxart’s principal competitors we shall now look closely at some recent partnership agreements signed by this group with other companies particularly relating to the development of a vaccine against Covid-19.
In 2020, the group notably prepared for the potential launch of its experimental vaccine against Covid-19 by expanding its partnership with the company Kindred Biosciences which is quoted on the Nasdaq. The objective of this partnership related to the manufacture of its oral vaccine candidate against the new corona virus and according to the terms, the Kindred factories would produce the bio-reactors for the clinical trials of Vaxart. In this way, the two companies would combine their efforts with the aim of increasing their capabilities in terms of vaccine production.
In the beginning of 2020 the Vaxart Group also became associated with Janssen Pharmaceutical Companies, a subsidiary of the group Johnson & Johnson, for the development of an oral vaccine against Covid-19.
Finally, still on the subject of the development of an anti-covid vaccine, Vaxart also signed a partnership with Emergent BioSolutions in March 2020 for the manufacture of this vaccine.
The principal shareholders in the Vaxart Group are currently as follows: SSgA Funds Management Inc with 8.02% of shares, The Vanguard Group with 4.19%, RTW Investments LP with 2.99%, VHCP Management LLC with 2.35%, RA Capital Management FP with 2.33%, BlackRock Fund Advisors with 1.89%, BML Capital Management LLC with 1.42%, Baker Bros Advisors LP with 1.19%, Geode Capital Management LLC with 1.05%, and T. Rowe Price Associates Inc with 1.03%.
To follow and study the Vaxart share price and possibly anticipate its future movements you should use a fundamental analysis with economic indicators and highly impactful events and announcements, as well as technical indicators relating to the trend, its volatility and the liquidity of the market.
As Vaxart is an American biotechnology group, its share price is of course quoted on the Nasdaq stock market, more precisely the Nasdaq Global Select Market which includes the principal companies from the technology sector worldwide. It is also important to note that this company is also included in the Nasdaq 100 stock market index due to its high stock market capital.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. {etoroCFDrisk}% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
